2017Äê6ÔÂ4ÈÕ
£¬£¬£¬£¬£¬£¬£¬µÚ14½ì¹ú¼ÊÌ×ʽ²¡¶¾´ó»áÓÚÃÀ¹ú¿°Èø˹ÖÝÀֳɾÙÐС£¡£¡£¹ú¼ÊÌ×ʽ²¡¶¾´ó»áÿÁ½Äê¾ÙÐÐÒ»½ì
£¬£¬£¬£¬£¬£¬£¬²Î»á³ÉÔ±Ö÷ÒªÀ´×ÔѧÊõ½çºÍ¹ú¼Ê×ÅÃû¶¯±£ÆóÒµ¡£¡£¡£±¾´Î´ó»á²Î»áÈËÊýÔ¼1200ÈË¡£¡£¡£

¾ÅÖÝku¿áÓι«Ë¾¸±¶­Ê³¤Ëï½øÖÒ¡¢¹ú¼ÒÊÞÓÃÒ©Æ·¹¤³ÌÊÖÒÕÑо¿ÖÐÐÄÖ÷ÈÎÌï¿Ë¹§²©Ê¿¡¢ÖÐÐÄÖ÷ÈÎÖúÀíÓöÐãÁᲩʿ¡¢ÉúÎ﹤³ÌÑо¿ËùËù³¤ÀîÏò¶«²©Ê¿¡¢¾ÅÖÝku¿áÓÎÖíÃçÊÂÒµ²¿×Ü˾Àí¿µóÆÀûµÈÊÜÑû³öϯµÚ14½ì¹ú¼ÊÌ×ʽ²¡¶¾´ó»á¡£¡£¡£

»áÉÏ
£¬£¬£¬£¬£¬£¬£¬¹ú¼ÒÊÞÓÃÒ©Æ·¹¤³ÌÊÖÒÕÑо¿ÖÐÐÄÖ÷ÈÎÌï¿Ë¹§²©Ê¿×ö¡¸PRRSV vaccine development and application in China
£¬£¬£¬£¬£¬£¬£¬ÖíÀ¶¶ú²¡ÒßÃçÔÚÖйúµÄÑз¢¼°Ó¦Óá¹Ö÷Ìⱨ¸æ¡£¡£¡£ÌïÖ÷ÈÎÔÚ±¨¸æÖÐÏÈÈÝÁËJXA1-PRRSVÒßÃçµÄÑз¢Àú³Ì¼°¹ú¼ÒÊÞÓÃÒ©Æ·¹¤³ÌÊÖÒÕÑо¿ÖÐÐÄ(nvc)¹ØÓÚÀàNADC30 PRRSVµÄÑо¿ÊÂÇé¡£¡£¡£

ÓÉÓڸò¡¶¾»ùÒò×éÌØÕ÷Óë2008ÄêÃÀ¹úÊ¢ÐÐµÄ NADC30 PRRSV ¶¾Öê×îΪ¿¿½ü
£¬£¬£¬£¬£¬£¬£¬Òò¶øµÃÃûΪ ÀàNADC30 PRRSV£¨NADC30-like PRRSV£©¡£¡£¡£2012Äê
£¬£¬£¬£¬£¬£¬£¬ÎÒ¹úÊ×´ÎÊèÉ¢µ½ ÀàNADC30 PRRSV
£¬£¬£¬£¬£¬£¬£¬ÏÖÔڸò¡¶¾ÒÑÔÚÎÒ¹ú´ó²¿·ÖÊ¡·ÝÊ¢ÐС£¡£¡£ÓëÒÔÍù PRRSV ¶¾Öê²î±ð
£¬£¬£¬£¬£¬£¬£¬¸Ã²¡¶¾ÓëÆäËû²¡¶¾ÖØ×é»úÂÊÏÔÖøÌáÉý
£¬£¬£¬£¬£¬£¬£¬¶¾ÖêÖ®¼ä¶¾Á¦²î±ð½Ï´ó
£¬£¬£¬£¬£¬£¬£¬ÉÌÆ·»¯ PRRSV ÒßÃç±£»£»
£»£»£»£»£»£»¤Á¦ÓÐÏÞ
£¬£¬£¬£¬£¬£¬£¬Òò´Ë
£¬£¬£¬£¬£¬£¬£¬ÀàNADC30 PRRSV ¸øÎÒ¹úµÄÉúÖíÑøÖ³Òµ´øÀ´ÖØ´óµÄ¾­¼ÃËðʧ¡£¡£¡£

½üÄêÀ´
£¬£¬£¬£¬£¬£¬£¬¹ú¼ÒÊÞÓÃÒ©Æ·¹¤³ÌÊÖÒÕÑо¿ÖÐÐÄ£¨NVC£©Î§ÈÆÎÒ¹ú ÀàNADC30 PRRSV »ùÒò×éÌØÕ÷¡¢Ê¢ÐйæÄ£¡¢Ö²¡Á¦¡¢ÉÌÆ·»¯ÒßÃç±£»£»
£»£»£»£»£»£»¤Á¦µÈÆ«Ïò¾ÙÐÐϵͳ»ù´¡Ñо¿
£¬£¬£¬£¬£¬£¬£¬ÔÚ¹ú¼ÊÉϱ¬·¢ÁËÆÕ±éµÄÓ°Ïì
£¬£¬£¬£¬£¬£¬£¬ÏêϸЧ¹ûÈçÏ£º

1.ÊèÉ¢²¡¶¾40ÓàÖê

2.ÉêÇë¹ú¼Ò·¢Ã÷רÀû3Ïî

3.³öÊ顶Öí×ÌÉúÓëºôÎü×ÛºÏÕ÷¡·×¨Öø1²¿

4.½ÒÏþSCIÂÛÎÄ7ƪ£º

¢Ù Li C, et al. Transbound Emerg Dis. 2016 Oct;63(5):474-9.

¢Ú Li X, et al. Springerplus. 2016 Sep 29;5(1):1677.

¢Û Sun Z, et al. Arch Virol. 2016 Aug;161(8):2257-61.

¢Ü Bai X, et al. Vaccine. 2016 Nov 4;34(46):5540-554Li5.

¢Ý Li X, et al. Infect Genet Evol. 2016 Dec 22. pii: S1567-1348(16)30550-0.

¢Þ Ji G, et al. Genome Announc. 2016 Apr 21;4(2). pii: e00303-16.

¢ß Li Y, et al. Genome Announc. 2016 May 5;4(3). pii: e00330-16.

¾­ÓɶàÄêµÄÁ¢Òìʵ¼ù
£¬£¬£¬£¬£¬£¬£¬¾ÅÖÝku¿áÓι«Ë¾ÔÚÖÖÖÖÁ¢Òìƽ̨½¨ÉèÓëÊÖÒÕÑз¢·½ÃæʵÏÖÁËÓë¹ú¼Ê½Ó¹ì
£¬£¬£¬£¬£¬£¬£¬Ïà¹ØÊÖÒÕЧ¹ûµÖ´ïÁ˺£ÄÚÁìÏÈ¡¢¹ú¼ÊÏȽøˮƽ
£¬£¬£¬£¬£¬£¬£¬²¢ÓµÓÐÌõ¼þÍêÕûµÄÑз¢¼°¹¤³Ì»¯¡¢¹¤Òµ»¯Ìõ¼þ¡£¡£¡£ÊÜÑû³öϯµÚ14½ì¹ú¼ÊÌ×ʽ²¡¶¾´ó»á²¢½ÒÏþÖ÷Ìⱨ¸æ
£¬£¬£¬£¬£¬£¬£¬ÒýÆðÁ˲λᵥλ¶Ô¾ÅÖÝku¿áÓι«Ë¾¼°NVCµÄ¸ß¶È¹Ø×¢
£¬£¬£¬£¬£¬£¬£¬Í¬Ê±Ò²¼«´óÌáÉýÁ˾ÅÖÝku¿áÓι«Ë¾¼°NVCÔÚ¹ú¼Ê¶¯±£ÁìÓòµÄ×ÅÃû¶È¡£¡£¡£